Home Tags Leonard Schleifer

Tag: Leonard Schleifer

Regeneron’s founders honored by Business Council

Leonard S. Schleifer, Regeneron’s president and CEO, and George D. Yancopoulos, president and chief scientific officer, were honored with the 2021 Westchester Global Leadership Laureate Award for their roles in developing Regeneron’s antibody treatment for Covid-19.

Westfair Businesspersons of the Year: Regeneron’s Leonard Schleifer and George Yancopoulos

The Tarrytown-based company has gone from being a tiny 1988 startup to a $50 billion market-cap business.

Regeneron strikes deal with Roche on Covid cocktail

The cocktail is needed to both protect against being infected by the Covid-19 virus and also provide a treatment should infection occur.

Westchester, HV notables named to state reopening advisory board

As the count of COVID-19 cases in the U.S. today passed the million mark, with 1,022,265 people confirmed as positive and a death toll...

Regeneron seeks a protect-and-treat antidote for COVID-19

https://www.youtube.com/watch?v=31i6p_stzW8 Tarrytown-based Regeneron is working to find a drug that has the potential to not only protect a person against the COVID-19 coronavirus, but also...

Equilibrium Brewery cuts ribbon at Middletown facility

The brewery in downtown Middletown will open its doors to the public in early 2017.

Regeneron’s Schleifer, Yancopoulos share Entrepreneur of Year award

Two founding physicians and scientists at the state's largest biotech employer are named top life sciences entrepreneurs for 2016.

Regeneron sales boom with drug launch

Regeneron Pharmaceuticals in Greenburgh raised its 2012 sales forecast for its year-old drug Eylea by $90 million to $115 million over its earlier forecast.

Regeneron Takes Top Spot in Science Magazine Survey

Regeneron Pharmaceuticals Inc., long considered to be the cornerstone of a fast-emerging biotechnology cluster here in the Hudson Valley, was ranked the number one employer in the global biopharmaceutical industry by Science magazine.

Eylea approved for use in Japan

Regeneron Pharmaceuticals Inc. announced today that Eylea was approved for the treatment of patients with neovascular, or wet, age-related macular degeneration (AMD) in Japan.